Dr. Reddy's Laboratories is a major Indian pharmaceutical company founded in 1984 and headquartered in Hyderabad. It has over 190 medications and 60 active pharmaceutical ingredients. The company has a global workforce of over 20,000 employees and a commercial presence in 26 countries. Dr. Reddy's Laboratories aims to bring new medicines to India at affordable prices. It has several subsidiaries and joint ventures around the world. The company produces generic medicines, APIs, differentiated formulations, and biosimilars. Its major competitors include Sun Pharma, Lupin, Aurobindo Pharma, and Cipla.

1. WELCOME
1/4/2017Manash Pratim Kalita,Roll No-198,Section-M4

2. Dr Reddy’s Laboratories
The Home-grown Pharmaceutical Giant
Company Based Research
Presentation
MANASH PRATIM KALITA
ROLL NO-198
SECTION-M4

3. Introduction
 Dr.Reddy’s laboratories is a premier and major Indian pharmaceutical
company headquartered in hyderabad
 Founded by Kallam Anji Reddy in 1984
 Over 190 medications, 60 active pharmaceutical ingredients(api) for drug
manufacture, diagnostic kits and critical care units
 To bring new molecules into the country at a price the common man can afford
 Global workforce-20000+
 Commercial presence-26 countries
1/4/2017Manash Pratim Kalita,Roll No-198,Section-M4

4. Group Companies
 Dr. Reddy's laboratories Australia pvt ltd, a wholly owned subsidiary of dr.
Reddy's laboratories ltd
 In china joint venture with Rotam group
 Dr. Reddy's operates in Germany through its subsidiary Betapharm
 Dr. Reddy’s laboratories ltd. decided to enter the market directly through a
joint venture with Venturepharm
 Dr. Reddy’s laboratories UK ltd was created with the acquisition of BMS
laboratories and its subsidiary meridian healthcare
1/4/2017Manash Pratim Kalita,Roll No-198,Section-M4

5.  Goal
 Good health
 Commitment
 That’s why the company believes in “Good health cant wait”
 Principles
 Empathy and Dynamism
 Purpose
 We accelerate access to affordable and innovative medicines because good
health cant wait
1/4/2017Manash Pratim Kalita,Roll No-198,Section-M4

6. Hierarchy and Organizational
Structure
CHAIRMAN
COO
GLOBAL HR
HEAD
EVP CFO
CO-CHAIRMAN
CUM CEO
Whole time directors
 Satish Reddy
 G V Prasad
Independent and non-whole time directors
 Dr.Omkar Goswami
 Anupam Puri
 Kalpana Morparia
 Dr. Bruce LA Carter
1/4/2017Manash Pratim Kalita,Roll No-198,Section-M4

7. Products and Services
 GENERICS- Omez (Omeprazole), Nise (Nimesulide),Ketorol
(Ketorolac Thromethamine), Stamlo (Amlodipine Besylate), Razo
(Rabeprazole)
 OVER THE COUNTER- Cetrine, Nise gel, Ibuclin and Novigan.US nicotine
replacement therapy transdermal patch named Habitrol.
 API(ACTIVE PHARMACEUTICAL INGREDIENTS)- caters to leading
innovator and generic companies across the US, Europe, Latin America, Japan,
Korea and other emerging markets such as steroids, peptides, complex long
chain synthesis and oncology
 BIOLOGICS- Biologics – large molecule protein therapies – for an effective
treatment that may have fewer side effects.
 DIFFERENTIATED FORMULATIONS- Custom Pharma Services (CPS)
1/4/2017Manash Pratim Kalita,Roll No-198,Section-M4

8. Major Competitors of the Company
 Sun Pharma
 Lupin
 Aurobindo Pharma
 Cipla
 Cadila
 Ranbaxy Labs
 Divis labs
International Competitors
 Abbot Laboratories
 Abeona Therapeutics
1/4/2017Manash Pratim Kalita,Roll No-198,Section-M4

9. NAME
SALES
TURNOVER
MARKET SHARE IN
%
Sun Pharma 7,614.46 8.137796832
Lupin 11,239.80 12.01230407
Dr Reddys Labs 10,207.70 10.90926851
Aurobindo Pharm 9,166.18 9.796165527
Cipla 12,034.06 12.86115303
Cadila Health 7,035.30 7.518831545
Ranbaxy Labs 6,864.94 7.336762815
Divis Labs 3,721.33 3.977094565
Piramal Enter 3,516.53 3.758218796
GlaxoSmithKline 2,826.21 3.020453556
Torrent Pharma 5,429.00 5.802131602
Glenmark 6,113.50 6.533676837
Alkem Lab 3,924.69 4.194431364
Biocon 2,323.60 2.483299501
Ajanta Pharma 1,551.76 1.658411445
TOTAL 93,569.06 100
8.137796832
12.01230407
10.90926851
9.796165527
12.86115303
7.518831545
7.336762815
3.977094565
3.758218796
3.020453556
5.802131602
6.533676837
4.194431364 2.483299501
1.658411445
MARKET SHARE IN %
Sun Pharma Lupin Dr Reddys Labs Aurobindo Pharm
Cipla Cadila Health Ranbaxy Labs Divis Labs
Piramal Enter GlaxoSmithKline Torrent Pharma Glenmark
Alkem Lab Biocon Ajanta Pharma
Market Share
1/4/2017Manash Pratim Kalita,Roll No-198,Section-M4

10. Ownership
PARTICULARS % OF SHARES
Promoter(individual and companies) 26.37
Indian financial institutions 2.83
Banks 0.15
Mutual funds 2.76
FIIs 35.41
NRIs 1.25
Foreign Companies 2.98
Indian Public 11.40
1/4/2017Manash Pratim Kalita,Roll No-198,Section-M4

11. Strength
1.Low cost chemotherapy medicine
2.Proprietary chiral and
biocatalysis know-how
3.Betapharma acquisition gives
access to European markets
Weakness
1.Government regulations and
national drug policy
2.Huge investment
3.Highly unpredictable sector
Opportunities
1.Oncology market entry
2.Partnership in bio-similar markets
3.Cost effective methodologies in
emerging markets
Threats
1.Preliminary investment very high
2.Patents
3.Foreign giant entry
1/4/2017Manash Pratim Kalita,Roll No-198,Section-M4

12. Financial Analysis
1.7101590481.8875074852.0380409912.1175990332.269833634
0
1
2
3
2011 2012 2013 2014 2015 2016 2017
DEBT
EQUITY
RATIO
1/4/2017Manash Pratim Kalita,Roll No-198,Section-M4

13. CSR Activities
 School-Community Partnership in Education
 Chindu
 Pudami Neighborhood Schools
 KARV – Kallam Anji Reddy Vidyalaya
 KARV-JC – Kallam Anji Reddy Vocational Junior College
 Youth
 Women
 Household
1/4/2017Manash Pratim Kalita,Roll No-198,Section-M4

14. CSR Expenditure
 2016---3.04%
 2014-15---1.74%
 2013-14---1.03%
 2012-13---1.33%
 CSR provisions in Companies Act,2013
 every company, private limited or public limited, which either has a net worth of Rs 500 crore or a
turnover of Rs 1,000 crore or net profit of Rs 5 crore, needs to spend at least 2% of its average net
profit for the immediately preceding three financial years on corporate social responsibility
activities
1/4/2017Manash Pratim Kalita,Roll No-198,Section-M4

15. Employee Benefits
1/4/2017Manash Pratim Kalita,Roll No-198,Section-M4

16. Economic Analysis
 High economies of scale
 Low cost products so tough entry for players
 Extensive R&D hence no threats from patent expiration
 Alliances, joint ventures or acquisition
 Easing of norms under “Make in India” programme
1/4/2017Manash Pratim Kalita,Roll No-198,Section-M4

17. Conclusion
 Made healthcare more affordable
 Giant Indian player in US, Russia and CIS countries
 FDA regulations getting tougher
 Currently focus is not only on foreign countries but also in India
 NYSE listed company
1/4/2017Manash Pratim Kalita,Roll No-198,Section-M4

18. THANK YOU
1/4/2017Manash Pratim Kalita,Roll No-198,Section-M4